EmphyCorp, Inc.

Drug

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Nasal Spray

and Oral Spray

Phase 1

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Plan

Χ

Χ

Χ

Х

Pilot Study

Phase 2

Χ

Χ

Orphan

Drug NDA

Χ

Χ

Χ

Х

Χ

Χ

Pilot Study

Pilot Study

Pilot Study

Pilot Study

(3) New Drug Patents for the Treatment of all Sinus

and Lung Diseases & Slowing/Stopping Lung Fibrosis

(1) US and (3) Chinese Approved Nasal Sprays

Phase 3

X - Pivotal

Phase III

Trial for NDA

Protocol

ready

Protocol

Ready

for Phase 3

in 2026

X

Protocol

Ready

Protocol

Ready

Protocol

Ready

NDA

X

EmphyCorp N115 Rx Nasal and Oral Spray Drug Pipeline w/ No Side Effects

10	/2 /	2()2	5		
s/F	lu)	(x	=	СО	mį	9

Improved Lung Function

(Hypoxemia, Dyspnea) Met (8) Medical Endpoints. Clinically

& Statistically Significant Results

FEV1, Coughing, Hypoxemia,

Dyspnea, and Sleeping Better

FEV1, Coughing, Hypoxemia,

Diabetic, Hypertensives and

Pregnant Women)

Dyspnea, Bronchodilator (Safe for

Expanded Phase 3 in 2026.

Met (8) Medical Endpoints

(10 Million US Patients)

Immediate Relief of Congestion,

Alleray symptoms

(Safe for 30 to 60 million US Diabetic, Hypertensives,

and Pregnant Women)

Increases Nasal Nasal Nitric Oxide

to kill Viruses/Shut IL-6

Increases Nasal Nitric Oxide to kill

Viruses/Shut IL-6

Discovered in Phase II Severe

COPD Patient Clinicals

Helps relieve symptoms

Helps relieve symptoms

Helps relieve symptoms

Protects Healthy Cells

Stops Nasal Bleeding

3 Million Patients Treated

(8) Drug Patents – (3) New Composition

Patents

Medical Endpoints

navirus/Flu) (x = completed)
Medical Endpoints Achieved
73% Reduction in Coughing &

Idiopathic Pulmonary Fibrosis

(ILD Orphan Drug Designation)

No Adverse Events Reported

Pulmonary Fibrosis & IPF

(ILD Orphan Drug Designation)

No Adverse Events Reported

Cystic Fibrosis

(ILD Orphan Drug Designation)

Moderate & Severe COPD Treatment

No Adverse Events Reported

(Can replace Sprays with Steroids and

PED3/PED4 Inhibitors)

Long COVID Treatment (No Adverse Events Reported

in a Small Clinical Trial)

Allergic Rhinitis

No Adverse Events Reported

(Can replace Nasal Sprays with Steroids,

Oxymetazoline, and Phenylephrine)

Influenza Treatment & Preventative

(No Adverse Effects)

COVID-19 Treatment

(No Adverse Effects in a Small Clinical Trial)

High Blood Pressure and Pulmonary

Hypertension Treatment

Alzheimer's

Concussions

Parkinson's

Cancer Pre-Treatment

Racehorses - Increase SaO2

Patented OTC Nasal Spray sold US/China

To Date: (28) Sets of Human Clinical Trials

completed. (6) Peer Reviews & 38 NIH studies

8 Drug Patents (3 New: Hypoxemia & Dyspnea & Coughing, Apoptosis of Myofibroblasts, Coronavirus